- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
TREATING LIFE
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 68 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove excessive cytokines and other inflammatory mediators from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents specializes in treating life-threatening conditions in the ICU and during open heart surgery. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology
- CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
- CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular
- CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
- CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference
- slider1.jpg
